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Abstract
Purpose—We evaluated X-ray repair complementing defective repair in Chinese hamster cells 1
(XRCC1) protein in head and neck squamous cell carcinoma (HNSCC) patients in association
with outcome.
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Experimental Design—XRCC1 protein expression was assessed by immunohistochemical
(IHC) staining of pretreatment tissue samples in 138 consecutive HNSCC patients treated with
surgery (n = 31), radiation (15), surgery and radiation (23), surgery and adjuvant chemoradiation
(17), primary chemoradiation (51), and palliative measures (1).
Results—Patients with high XRCC1 expression by IHC (n = 77) compared with patients with
low XRCC1 expression (n = 60) had poorer median overall survival (OS; 41.0 months vs. OS not
reached, P = 0.009) and poorer progression-free survival (28.0 months vs. 73.0 months, P =
0.031). This association was primarily due to patients who received chemoradiation (median OS
of high- and low-XRCC1 expression patients, 35.5 months and not reached respectively, HR 3.48;
95% CI: 1.44–8.38; P = 0.006). In patients treated with nonchemoradiation modalities, there was
no survival difference by XRCC1 expression. In multivariable analysis, high XRCC1 expression
and p16INK4a-positive status were independently associated with survival in the overall study
population (HR = 2.62; 95% CI: 1.52–4.52; P < 0.001 and HR = 0.21; 95% CI: 0.06–0.71; P =
0.012, respectively) and among chemoradiation patients (HR = 6.02; 95% CI: 2.36–15.37; P <
0.001 and HR = 0.26; 95% CI: 0.08–0.92, respectively; P = 0.037).
Conclusions—In HNSCC, high XRCC1 protein expression is associated with poorer survival,
particularly in patients receiving chemoradiation. Future validation of these findings may enable
identification of HNSCC expressing patients who benefit from chemoradiation treatment.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is diagnosed in approximately half a
million individuals worldwide annually, accounting for 5% of malignancies and more than
4% of cancer deaths (1). Over the past decade, concomitant chemoradiation therapy (CRT)
has emerged as the standard of care in locally advanced HNSCC for organ preservation,
treatment of unresectable disease, and as adjuvant therapy in resected high-risk disease (2).
However, a proportion of patients will not respond to CRT. Furthermore, CRT has
significant short- and long-term treatment-related morbidities and complications.
Identification of markers which predict for sensitivity to CRT will help select patients who
benefit from it, while avoiding toxicity among nonresponders.
Resistance to CRT may occur due to increased tolerance to DNA damage resulting from a
highly efficient DNA repair capacity. X-ray repair complementing defective repair in
Chinese hamster cells 1 (XRCC1) protein is involved in base excision repair (BER) and
single-strand break (SSB) repair by acting as a scaffold for BER/SSB repair protein
complexes (3, 4). In preclinical studies, changes in XRCC1 gene (4, 5) and protein (6)
expression alters the sensitivity of cells to radiation and chemotherapeutic agents such as
cisplatin. Clinical studies of cervical carcinoma treated with neoadjuvant platinum-based
chemotherapy and laryngeal cancer treated with radiation have reported better outcomes in
patients with low-XRCC1 protein expression (7, 8). Presence of XRCC1 single-nucleotide
polymorphisms (SNP) have been shown to be associated with cancer susceptibility (9–11) as
well as treatment outcomes after platinum-based CRT, induction chemotherapy, and
radiotherapy (12–17).
We, therefore, investigated XRCC1 protein expression and its relationship to clinical factors
and treatment outcomes in HNSCC. The specificity of the XRCC1 antibody was shown. In
addition, 3 germline XRCC1 SNPs, which are known to be associated with HNSCC
susceptibility, were evaluated to determine their association with XRCC1 protein expression
and treatment outcome.
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The Carolina Head and Neck Cancer (CHANCE) study was a population-based case–control
study of incident HNSCC conducted from 2002 to 2006 in North Carolina (18). All patients
enrolled in the CHANCE study and treated at the University of North Carolina at Chapel
Hill (UNC-CH) were included in our study. Clinical information was abstracted from patient
medical records. Survival data were obtained from patient medical records, the Social
Security Death Index, and local obituaries. Treatment decisions were recommended by the
UNC Head and Neck multidisciplinary team and individualized according to patient age,
tumor extent, site, comorbidities, and performance status. The response to treatment was
assessed radiologically at 6 to 12 weeks after treatment completion and recorded as follows:
(i) complete response (CR) to nonsurgical treatment, (ii) persistent disease after nonsurgical
treatment, (iii) complete surgical excision with clear margins, (iv) surgical excision with
positive margins which were subsequently resected, and (v) surgical excision with positive
margins which were not resected. This study was reviewed and approved by the University
of North Carolina Biomedical Institutional Review Board.
Tissue microarray preparation
Tissue microarrays (TMA) were constructed from formalin-fixed paraffin-embedded tumor
blocks. Hematoxylin and eosin sections of tumors of all patients were reviewed by one
pathologist (W.K.F.) to confirm the original diagnosis, and a target area was identified in the
donor block. TMAs were constructed using 1-mm cores on the manual tissue microarrayer-1
from Beecher Instruments and were made in triplicate to account for potential staining
heterogeneity and potential loss of tissue during processing. Sequential 4-μm sections were
cut from each TMA.
Human papillomavirus in situ hybridization
Slide deparaffinization, conditioning, and staining with INFORM HPV III Family 16 Probe
(B; Ventana Medical Systems) were done on the Ventana Benchmark XT Autostainer
according to the manufacturer's protocol. The probes have affinities to human
papillomavirus (HPV) genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66. Slides
were scored as positive for HPV if a punctate or diffuse pattern of signal were observed in
the tumor nuclei.
Immunohistochemical staining for XRCC1 and p16INK4a
Immunohistochemical (IHC) staining of XRCC1 protein and of the CDK inhibitor p16INK4a
protein, a biomarker of HPV- E7 oncoprotein activity (19), was carried out in the Bond
Autostainer (Leica Microsystems Inc.) according to the manufacturer's protocol. Briefly,
slides were dewaxed in Bond Dewax solution (AR9222) and hydrated in Bond Wash
solution (AR9590). Antigen retrieval for XRCC1 was done for 20 minutes at 100°C in
Bond-Epitope Retrieval solution 2 (pH = 9.0, AR9640). Slides were incubated with XRCC1
antibody (H-300; dilution 1:100, Santa Cruz Biotechnology, Inc.) for 1 hour. Breast cancer
tissue was used as a positive control. Antigen retrieval for p16INK4a was done for 30 minutes
at 100°C in Bond-Epitope Retrieval solution 1 (pH 6.0, AR9961) after which slides were
incubated with p16INK4a antibody (Mouse monoclonal anti-p16 antibody MAB4133,
Chemicon Internationa/Millipore Corporation) for 15 minutes. Antibody detection for
XRCC1 and p16INK4a was done using the Bond Polymer Refine Detection System
(DS9800). Image acquisition was done using ScanScope CS (Aperio Technologies). After
completion of IHC, slides are stored at room temperature in our laboratory and a virtual
scanned copy of all TMA slides will be kept indefinitely.
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Evaluation of XRCC1 protein expression and p16INK4a expression
XRCC1 and p16INK4a staining was assessed by a pathologist (K.F.) with no prior knowledge
of the clinical data. The percentage of tumor cells with positive nuclei was determined by
scoring 10 microscopic fields of 100 tumor cells each. Samples were also scored for the
intensity of staining from 0 (no staining) to 3+ (strong staining). The Allred score was
derived from the percentage of XRCC1-staining tumor cells and staining intensity (20).
Using the median Allred score as the cutoff, XRCC1 expression status was dichotomized
into high and low expression. Tumor p16INK4a expression was dichotomized as p16INK4a
positive (strong nuclear or cytoplasmic staining in 70% or more tumor cells) or p16INK4a
negative.
RNAi-mediated knockdown of XRCC1
UM38 head and neck cancer cell lines grown in Dulbecco's modied Eagle's medium
containing 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, and 2 mmol/L L-
glutamine were used to examine XRCC1 knockdown using ON-TARGETplus siRNA
SMART pool or scrambled control from Dharmacon, Inc. Lipofectamine LTX Plus
(Invitrogen) in OptiMEM medium was used as a transfecting agent (vehicle). Cells were
incubated with XRCC1 siRNA for 48 hours for mRNA and 72 hours for protein detection.
Controls included untreated cells, vehicle alone treated, and scrambled siRNA-treated
groups. At the end of 48 hours incubation with siRNA or controls, mRNA was isolated from
the cells using the Qiagen RNeasy Mini Kit (Qiagen). After NanoDrop quantification,
cDNA was prepared (iScript cDNA; BioRad). Quantitative reverse transcriptase PCR was
carried out using an XRCC1 Assay on Demand (Applied Biosystems) on a LightCycler 480
(Roche Applied Science) using 18S as an internal control. For XRCC1 protein expression, at
the end of 72 hours of incubation with siRNA, cells were lysed with
radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase
inhibitors and protein content was quantified by BCA assay (Thermo Scientific). Western
immunoblot analysis was carried out by probing with rabbit anti-XRCC1 primary antibody
(1:5,000) (Santa Cruz Biotechnology Inc.) with an internal loading control (mouse anti-
Actin, mAb1501l; 1:10,000; Chemicon, Billerica) followed by secondary antibodies goat
anti-rabbit IgG and goat anti-mouse IgG (1:10,000), respectively. Positive control for
Westerns was 293T lysate which overexpressed mouse XRCC1, commercially available
(Santa Cruz Biotechnology Inc.).
Immunocytochemical analysis of RNAi-mediated knockdown of XRCC1 in UM38 cells
To show specificity of the antibody against native XRCC1, UM38 cells were transfected as
above and 72 hours after treatment, cells were spun onto slides using cytospin,
permeabilized with 1% triton-X-100, and stained using anti-XRCC1 (1:500; Santa Cruz
Biotechnology Inc.) and fluorescein isothiocyanate (FITC) conjugated goat anti-rabbit
secondary (Santa Cruz, 1:200). 4′, 6-diamidino-2-phenylindole was used to stain nuclei. At
least 5 digital photomicrographs of each condition were captured using a Nikon Eclipse
TS100 equipped with a digital camera using TSView7 software, Version 6.0.2.1 (Tucsen
Imaging Technology). Two representative 20× images for each condition are shown. Images
were merged using ImageJ software. Whole 20× fields were quantified for fluorescent FITC
intensity using imageJ.
Western immunoblot analysis of XRCC1 protein in patient specimens
As additional controls for the specificity of the XRCC1 antibody used in this study, we
identified 4 cases (2 high and 2 low expression), in which patients from the TMA cohort had
separately banked frozen tissue, suitable for Western immunoblot analysis of XRCC1
protein from tumor lysates. Frozen tumors from patients were lysed in RIPA, run on 10%
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SDS-PAGE gels, and transferred to nitrocellulose and probed along with positive control
lysate as above.
DNA extraction and genotyping
Three SNPs in XRCC1 were evaluated: RS1799782, RS25496, and RS 2682558 as part of
the CHANCE study. Genomic DNA was obtained for genotyping from peripheral blood of
patients by a salt precipitation method using Gentra's Puregene chemistries. Genotyping was
done at the UNC-CH Mammalian Genotyping Core Facility, using the Illumina GoldenGate
genotyping assay. Blind duplicates of 109 samples were genotyped to verify reliability of
genotype calls.
Statistical analyses
Baseline characteristics of patients with high versus low XRCC1 expression were compared
using Fisher's exact test for discrete variables and the independent samples T-test for
continuous variables. Patients with no available XRCC1 data were excluded from all study
analyses. The primary objective was to determine the association between overall survival
(OS) and XRCC1 protein expression. Secondary objectives were, first, to determine the
association of XRCC1 protein expression with progression-free survival (PFS) and the
response to primary radiation (RT) and primary chemoradiation (CRT); and second, to
determine the association of XRCC1 SNPs with protein expression and OS.
OS was defined as the time from diagnosis to date of death from all causes, or censored at
the last documented follow-up date. PFS was calculated from the date of diagnosis to the
date of disease progression, or death from all causes, or censored at the last documented
follow-up date. Distributions of OS and PFS were estimated using the Kaplan–Meier
method and log-rank statistics were used to assess differences between survival curves.
Univariate and multivariable analyses of the endpoints of mortality and progression or death
were done using Cox proportional hazards logistic regression models. Factors included in
the multivariable model were any variable(s) with significant univariate associations with
mortality, as well as tumor site, stage, XRCC1 expression status, and p16INK4a expression
status. The same analyses were then repeated for the subgroups of patients treated with
primary or adjuvant CRT (“CRT cohort”) and with non-CRT modalities (consisting of
surgery only, radiation only, or surgery plus radiation; “non-CRT cohort”).
When XRCC1 and p16INK4a protein expression were both independently associated with
mortality, we divided our study population into 4 groups on the basis of their expression
status of either marker as follows: (i) p16INK4a negative and XRCC1 high, (ii) p16INK4a
positive and XRCC1 high, (iii) p16INK4a negative and XRCC1 low, and (iv) p16INK4a
positive and XRCC1 low. Survival of these 4 groups was evaluated.
All reported P values are 2-sided and P < 0.05 was considered significant. Kaplan–Meier
analyses were done using R version 2.5.1, all other statistical analyses were done with SPSS
software (version 18, SPSS Inc.).
Results
Patient characteristics
A total of 143 patients were treated at UNC-CH during the CHANCE study. Five patients
with no available XRCC1 data were excluded. The characteristics of the remaining 138
patients are listed in Table 1. Of these, 137 patients with nonmetastatic disease were treated
with curative intent, 1 patient had metastatic (stage IVc) disease and was treated palliatively.
This patient was excluded from further analyses. Patients who underwent primary or
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adjuvant CRT/RT received a median radiation dose of 70 Gy (range 60–74 Gy) and 66 Gy
(range 50–70 Gy), respectively. Of patients who underwent concurrent CRT, the majority (n
= 64, 94%) received platinum-based chemotherapy, 2 patients received nonplatinum
treatments (1 with nonplatinum chemotherapy and 1 with cetuximab), and in 2 patients
(3%), information on the chemotherapy used was not available.
HPV and p16 immunostaining
There were 13 p16-positive cases in the entire cohort (9.5%), and among oropharynx cases,
11 of 38 (28.9%) were p16 positive. P16 status was significantly associated with
oropharyngeal tumor site (P < 0.001). HPV infection and p16 expression status were
significantly associated, agreeing in 125 cases (92%; P < 0.001).
Evaluation of XRCC1 antibody
We showed specificity and sensitivity of the antibody against XRCC1 using patient samples
and a head and neck cancer cell line (Supplementary Fig. S1). Using anti-XRCC1 in
Western immunoblot analysis of XRCC1 protein from frozen patient tumor lysates,
identified from TMA data as high or low XRCC1 expressers (and confirmed by mRNA
expression analysis, data not shown), we detected 2 bands at 90 and 75 to 80 kDa which
correlated with bands in positive control 293T cells overexpressing XRCC1. Elevated levels
of XRCC1 are confirmed in tumors a priori identified as “high” XRCC1 expressers, which
supports IHC presented herein. Next, XRCC1-specific mRNA knockdown was achieved
with an 89% reduction compared with scrambled siRNA in UM38 head and neck cells using
RNAi-mediated knockdown reagents. Using this experimental paradigm, immunoblot and
immunocytochemical (ICC) detection of XRCC1 was undertaken in control and siRNA
knockdown conditions in UM38 cells. Western immunoblot showed 47% to 78%
knockdown of XRCC1 bands identified in UM38 cells and 293T overexpressing XRCC1-
positive controls (80 and 90 kDa, respectively). Anti-XRCC1 ICC clearly detected XRCC1-
positive FITC staining in vehicle (not shown) and scrambled RNAi-treated UM38 cells.
Most striking, XRCC1-positive staining is reduced to essentially undetectable levels in cells
with XRCC1 knockdown. Taken together, these data suggest that anti-XRCC1 is, indeed,
identifying XRCC1 protein in human tumor samples and human head and neck protein
lysates, as well as conditions in which staining is lost in cells with native XRCC1 depleted
showing specificity of this antibody.
Clinical pathologic data and XRCC1 protein expression
Using IHC, XRCC1 showed baseline nuclear staining in almost all patients (n = 135,
97.8%). XRCC1 protein expression was more prominent in the parabasal cells in the lower
half of the epithelium at lower staining intensities (1+, 2+), whereas at high staining
intensity (3+), XRCC1 expression was present throughout the epithelium (Fig. 1A). The
median percentage of positive tumor cells was 86.7% and median staining intensity was 3+.
The distribution of Allred scores was heavily skewed, with a median Allred score of 8
(range 0–8, Fig. 1B). Using this median score as a cutoff, there were 77 and 61 patients in
the high (score = 8) and low (score <8) XRCC1 expression groups, respectively. There was
no significant difference in age, gender, smoking status, tumor site, and stage between the
high- and low-XRCC1 expression groups (Table 1).
Treatment modality and XRCC1 expression
Patients in the CRT group (n = 68), as compared with the non-CRT group (n = 69), were
younger (age <60 years, 69% vs. 46%, P = 0.009), more likely to be male (78% vs. 58%, P =
0.017), and had more advanced stage tumors (93% vs. 43%, P < 0.001). Compared with the
non-CRT group, more CRT group patients had oropharynx or hypopharynx tumors, whereas
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less had oral cavity tumors (P < 0.001). There was a trend toward a higher proportion of
CRT group patients having high XRCC1 expression compared with non-CRT group patients
(65% vs. 48%, respectively, P = 0.058; Supplementary Table S1).
Treatment response and XRCC1 protein expression
Forty-six of 66 (70%) patients treated with primary CRT and primary RT had a CR to
treatment, 16 (24%) had persistent disease. Response status was unknown in 4 patients.
There was no relationship between treatment response and XRCC1 expression status (CR =
73% and 75% for low- and high-XRCC1 expression, respectively, P = 0.488). Assessing
primary CRT patients independently, there was still no relationship between XRCC1
expression and response (CR = 73% and 78% for low- and high-XRCC1 expression, P =
0.540).
Survival and XRCC1 protein expression
The median follow-up was 66.0 months (range: 39.0–87.0 months). In the overall study
population, median OS was 73.0 months [95% CI: 47.0 months–not reached (NR)], 5-year
OS was 58%, and median PFS was 47.0 months (95% CI: 29.0 months–NR). High
expression of XRCC1 was significantly associated with adverse OS. Median OS for patients
with high XRCC1 expression was 41.0 months (95% CI: 28.0 months–NR), whereas median
OS was not reached (95% CI: 73.0 months–NR) for patients with low XRCC1 expression (P
= 0.009). Stratifying the cohort by treatment modality (CRT vs. non-CRT), we found the
association of XRCC1 expression with OS was related to the treatment group. Of patients
who received CRT, median OS for patients with high XRCC1 expression was 35.5 months
(95% CI: 28.0–66.0 months), whereas median OS was not reached (95% CI: 68.0 months–
NR) for patients with low XRCC1 expression (P = 0.003). Five-year OS was 35% and 79%
in high- and low-XRCC1 expression groups, respectively. In contrast, in patients treated
with non-CRT modalities, there was no significant difference in OS between high-and low-
XRCC1 expression patients, with 5-year OS of 58% and 60%, respectively (P = 0.674).
Figures 2A–C show the Kaplan–Meier curves for OS in the overall, CRT, and non-CRT
cohorts, respectively.
As with OS, patients with high XRCC1 expression had poorer median PFS compared with
patients with low XRCC1 expression [28.0 months (95% CI: 20.0–66.0 months] and 73.0
months (95% CI: 47.0–NR), respectively; P = 0.031; Fig. 2D). This association of XRCC1
expression with PFS was once again accounted for by the subgroup of patients who received
CRT. In this group, PFS was 28.0 months (95% CI: 17.0–62.0 months) in patients with high
XRCC1 expression and was not reached (95% CI: 59.0 months–NR) in patients with low
XRCC1 expression (P = 0.022; Fig. 2E). Five-year PFS was 33% and 62% in XRCC1 high
and low expression groups, respectively. In patients treated with non-CRT modalities, there
was no significant difference in PFS between high- and low-XRCC1 expression patients,
with 5-year PFS of 48% and 52%, respectively (P = 0.577; Fig. 2F).
Univariate and multivariable analyses
The univariate relationships with mortality are shown in Table 2. In the whole cohort, T3–
T4 tumors, advanced stage (stage III/IV) disease, and high XRCC1 protein expression were
associated with increased risk of death (HR = 1.94; P = 0.010; HR = 1.79; P = 0.049 and HR
= 1.97; P = 0.011, respectively). In the CRT cohort, only XRCC1 protein expression was
associated with mortality (HR = 3.48; P = 0.006). There was no association of disease stage
with survival, however, only 5 patients had early-stage disease in the CRT group.
In a multivariable Cox regression model (Table 3), in the overall study population, high
XRCC1 expression was independently associated with mortality (HR = 2.62; 95% CI: 1.52–
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4.52; P <0.001). Late-stage disease (stage III/IV) and positive p16INK4a status were also
associated with mortality (HR = 1.86, 95% CI: 1.02–3.39; P = 0.043 and HR = 0.21; 95%
CI: 0.06–0.71; P = 0.012, respectively). In addition, high XRCC1 expression was
independently associated with increased risk of disease progression or death (HR = 2.04;
95% CI: 1.25–3.33; P = 0.004).
Restricting the multivariable analysis to the CRT cohort, XRCC1 expression status remained
strongly associated with the endpoints of mortality as well as disease progression or death,
independent of stage, tumor site, and p16INK4a expression status (HR = 6.02; 95% CI: 2.36–
15.37; P < 0.001 and HR = 3.37; 95% CI: 1.57–7.23; P = 0.002, respectively, Table 3). In
contrast, in the non-CRT cohort, there was no association of XRCC1 expression status with
mortality (HR = 1.69; 95% CI: 0.77–3.72; P = 0.189).
Relationship of XRCC1 and p16INK4a expression status with survival
Among the 4 groups as previously defined, survival was lowest in the p16INK4a-negative/
XRCC1-high group (n = 64), and highest in the p16INK4a-positive/XRCC1-low group (n =
2) (5-year OS 35% and 100%, respectively, P = 0.001). Among patients who were either
p16INK4a positive/XRCC1 high (n = 11) or p16INK4a negative/XRCC1 low (n = 59), 5-year
OS was similar and intermediate (5-year OS 70% and 67%, respectively, Fig. 3). One
patient with no available p16INK4a data was excluded from this analysis.
SNP analysis
The frequency of the different gene polymorphisms are shown in Supplementary Table S2.
No patients had minor alleles for RS25496. There was no relationship of RS1799782, a SNP
encoding an amino acid change at position 194, and XRCC1 protein expression, as
measured by the Allred score. Presence of at least 1 minor allele for RS2682558 was
associated with lower XRCC1 protein expression compared with the presence of only
common alleles, suggesting that perhaps this allele located in the 3′-untranslated region
(UTR) is associated with a regulatory element for the gene (Allred score 7.31 vs. 6.56, P =
0.038). Twenty-seven of 137 (19%) patients did not have available data for SNP analysis.
There was no relationship of RS1799782 with mortality in the whole cohort. Among
patients who underwent CRT, RS1799782 showed a trend toward increased mortality (Table
2) and was significantly associated with disease progression or death (HR = 2.77; 95% CI:
1.05–7.29; P = 0.040). Although these data are insufficient to support that the Arg194Trp
allele encodes a protein with increased activity, the phenotype associated with Arg194Trp
mirrors that of increased protein abundance. In parallel, patients with at least 1 variant allele
for RS2682558 had lower mortality (Table 2) and lower disease progression or death
compared with patients with only common alleles, consistent with lower XRCC1 protein
expression, but this was not statistically significant (median OS 69 months vs. NR,
respectively, P = 0.233 for whole cohort and OS 63 months vs. NR respectively, P = 0.190
for CRT cohort).
Discussion
In this study, we investigated the expression of XRCC1 in HNSCC patients and its
association with clinicopathologic factors and outcome. Our results show that XRCC1
protein expression is common in HNSCC and that high XRCC1 protein expression,
regardless of primary tumor site, stage, and p16INK4a status confers poorer survival as
compared with low XRCC1 expression. Furthermore, this association was strongest in the
subgroup of patients who received CRT.
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XRCC1 facilitates efficient DNA damage processing and is,therefore,especially
pertinentinpatientsundergoing CRT (3, 4, 21). Ionizing radiation kills cells by inducing
DNA damage such as base damage, SSB, double-strand breaks, and interstrand DNA cross-
links. Chemotherapy, particularly platinum-based chemotherapy, binds to DNA forming
DNA adducts, which distort DNA structure, causing damage and cell death. Combining
chemotherapy with radiation greatly increases the overall cytotoxic effect of radiotherapy by
inducing further DNA damage and interfering with DNA repair. This is mitigated to a
certain extent by nonspecific DNA repairsystemssuchasnucleotideexcisionrepair(NER) and
BER multistep enzymatic complexes. Therefore, high XRCC1 expression may increase the
DNA repair capacity of tumor cells leading to increased tolerance to DNA damage from
CRT. Our study findings of high XRCC1 protein expression being associated with poorer
survival after CRT areconsistentwiththishypothesisaswellaspreviousreports (7, 8). Our study
also shows that the coding SNP Arg194Trp is associated with treatment outcome among
CRT patients, whereas the noncoding RS2682558 in the 3′-UTR may have a regulatory role
and thus affect XRCC1 protein expression levels. Other studies have shown that XRCC1
Arg194Trp was associated with treatment response to platinum-based chemotherapy and
may predict for PFS (16, 17).
Despite the strong association between XRCC1 protein expression status and survival, we
were not able to show any relationship between XRCC1 expression and response to primary
CRT or RT. Response to CRT/RT was assessed 6 to 12 weeks after treatment completion,
and categorized as either CR or persistent disease. From a clinical standpoint, this was to
facilitate planning for early surgical salvage of patients with residual disease. However,
assessment of response is often difficult in HNSCC in which imaging may not always be
accurate, particularly in the immediate postradiation period. Furthermore, some patients take
longer to respond completely to CRT/RT and may, therefore, have been inappropriately
categorized as persistent disease at the 6- to 12-week posttreatment time point.
Presence of HPV has been established as a favorable prognostic factor in oropharyngeal
HNSCC (19, 22, 23). p16INK4a IHC has been shown to correlate with HPV status (19,22)
and patients with HPV-DNA positive and p16 expressing tumors, inparticular, have a
favorable prognosis(23). Consistent with previous studies, our results showed that p16INK4a-
positive status was associated with reduced risk of death. Interestingly, XRCC1 expression
status was able to further discriminate within each p16INK4a category. Among p16INK4a-
positive patients, who were expected to have good prognosis, patients with high XRCC1
expression had poorer survival compared with patients with low XRCC1 expression.
Furthermore, survival was similar between patients who were p16INK4a negative/XRCC1
low and p16INK4a positive/XRCC1 high, implying XRCC1 expression status has significant
prognostic implications. These findings are consistent with recent reports of subsets of HPV-
positive patients with differing survival outcomes, depending on factors such as Bcl2
expression, epidermal growth factor receptor expression, and smoking history (19, 22, 24–
26).
Nevertheless, other DNA repair enzymes may also influence treatment outcomes and require
consideration. PARP-1 is involved in DNA repair and is required for the assembly and
stability of XRCC1 (27, 28). ERCC1 is one of the key rate-limiting enzymes involved in
NER and studies in HNSCC have shown that low ERCC1 levels are associated with good
outcomes from CRT (29) and induction chemotherapy (30). Enzymes that modulate the
availability of platinum compounds (such as glutathione S-transferase π) or modulate cell
death and apoptosis (Bcl-2 and p53) have also been reported to affect the treatment
outcomes in HNSCC (27, 31–35).
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This study had several limitations. First, the study was retrospective and comprised a
heterogeneous cohort of HNSCC patients of different stages, tumor sites, and treatments,
although the baseline characteristics of patients in the high and low XRCC1 expression
cohorts were similar. Second, the study population was divided into high- and low-XRCC1
expression cohorts using the population median score as the cutoff point. We believe that
this use of the Allred score is clinically relevant because it defines 2 distinct patient
populations with different IHC staining patterns of XRCC1 expression: (i) homogenous and
intense staining throughout the epithelium; and (ii) heterogeneous (average of <67% of
tumor cells stained) and/or lower intensity staining (average intensity <3). This makes
XRCC1 staining evaluation a potentially useful biomarker in HNSCC, as there is little
ambiguity with regard to high-versus low-XRCC1 expression status. Third, only one
antibody was used for XRCC1 IHC, however, we showed its specificity for XRCC1 using
Western immunoblot of patient tumors, as well as Western and immunocytochemical
analysis of RNAi-mediated knockdown of XRCC1 in a head and neck cancer cell line. Our
data showing loss of native XRCC1 detection after RNAi support that this antibody, indeed,
is detecting specifically XRCC1. Fourth, the non-CRT cohort consisted of patients treated
with 3 different treatment modalities and thus it may have been inappropriate to analyze
them as a single group. Fifth, we did not have information on tumor differentiation and were
unable to correlate XRCC1 expression to tumor differentiation or assess its effect on
survival.
Taken together, our findings presented herein suggest that XRCC1 may be an important
biomarker in HNSCC. Assessment of XRCC1 protein expression status by IHC may be
useful in clinical decision making. Patients with high expression may have poorer outcomes
from CRT, although still being subject to toxicity, and thus could be directed to alternative
treatment modalities and/or clinical trials. Conversely, patients with low XRCC1 expression
may benefit from CRT, particularly if they are also p16INK4a-positive. Future studies will be
required to define the role of XRCC1, as a prognostic or predictive marker, in different
tumor sites and for different treatment modalities, and also to address the interactions and
roles that different repair proteins and prognostic markers may have in determining the
outcome of CRT in HNSCC.
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There are few established prognostic factors in head and neck squamous cell carcinoma
(HNSCC). p53 mutations in HNSCC have been shown to be associated with adverse
prognosis, independent of tumor primary site, whereas human papillomavirus (HPV) is a
favorable prognostic factor in oropharyngeal HNSCC. Recent studies have shown that
treatment outcomes in HNSCC may be modulated by a combination of prognostic
factors. X-ray repair complementing defective repair in Chinese hamster cells 1
(XRCC1) protein is involved in DNA base excision and single-strand break repair and
may, therefore, modulate chemoradiation outcomes by affecting efficient DNA damage
repair. Our study shows that high XRCC1 protein expression is associated with poorer
survival in HNSCC, particularly in patients undergoing chemoradiation. Furthermore,
this association was independent of HPV status, as assessed by p16
immunohistochemistry, and, importantly, XRCC1 protein expression status was able to
discriminate within each p16 category. Taken together, as patients with high XRCC1
expression managed with chemoradiation may have poorer outcomes, although still
susceptible to the same risk of toxicity, they may benefit from alternative management
strategies.
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A, representative examples of XRCC1 immunostaining in head and neck squamous cell
carcinoma at different staining intensities. i, intensity 0; ii, intensity 1+; iii, intensity 2+; and
iv, intensity 3+.
Magnification 200×. B, distribution of XRCC1 Allred score (range 0–8) in the overall study
population.
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Kaplan–Meier estimates of the probability of overall survival (A–C) and PFS (D–F)
according to XRCC1 expression in whole cohort (A, D), CRT cohort (B, E), and non-CRT
cohort (C, F).
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Kaplan–Meier estimates of the probability of overall survival in patients who are (i)
p16INK4a positive, XRCC1 low; (ii) p16INK4a positive, XRCC1 high; (iii) p16INK4a
negative, XRCC1 low; and (iv) p16INK4a-negative, XRCC1-high.
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Table 1
Patient characteristics in whole cohort and by XRCC1 expression status
Characteristics All patients (n = 138) Low XRCC1 (n = 61) Number (%) High XRCC1 (n = 77) P
Age, y 57 (median) Mean 59 Mean 56 0.105
    <60 80 (58) 33 (54) 47 (61) 0.488
    ≥60 58 (42) 28 (46) 30 (39)
Sex
    Male 94 (68) 43 (70) 51 (66) 0.713
    Female 44 (32) 18 (30) 26 (34)
Mean no. pack-years smoked 40 40 39 0.842
Smoking history
    Yes 126 (91) 56 (92) 70 (91) 1.000
    No 12 (9) 5 (8) 7 (9)
Alcohol
    Yes 93 (67) 46 (75) 47 (61) 0.100
    No 45 (33) 15 (25) 30 (39)
Site
    Larynx 35 (25) 12 (20) 23 (30)
    Oral cavity 57 (41) 31 (51) 26 (34) 0.235
    Oropharynx 38 (28) 15 (24) 23 (30)
    Hypopharynx 8 (6) 3 (5) 5 (6)
Tumor status
    T1–2 67 (49) 30 (49) 37 (48) 1.000
    T3–4 71 (51) 31 (51) 40 (52)
Nodal status
    N0–1 81 (59) 37 (61) 44 (57) 0.729
    N2–3 57 (41) 24 (39) 33 (43)
Stage
    Early (I, II) 44 (32) 20 (33) 24 (31) 0.856
    Late (III, IV) 94 (68) 41 (67) 53 (69)
Treatment
    Surgery 31 (22) 18 (29) 13 (17) 0.090
    Radiation 15 (11) 7 (11) 8 (10)
    Surgery + RT 23 (17) 11 (18) 12 (16)
    Surgery + CRT 17 (12) 9 (15) 8 (10)
    Primary CRT 51 (37) 15 (25) 36 (47)
    Palliative 1 (1) 1 (2) 0
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